Search publications

Publications

  • Santos-Gómez A, Miguez-Cabello F, García-Recio A, Locubiche S, García-Díaz R, Soto V, Guerrero-López R, Julià-Palacios NA, Ciruela F, Garcia-Cazorla A, Soto D, Olivella M and Altafaj X.

    Disease-associated GRIN protein truncating variants trigger NMDA receptor loss-of-function

    HUMAN MOLECULAR GENETICS . 29(24): 3859-3871. Number of citations: 19

    [doi:10.1093/hmg/ddaa220]

  • Garcia-Cazorla A, Verdura E, Julià-Palacios NA, Anderson EN, Goicoechea L, Planas-Serra L, Tsogtbaatar E, Dsouza NR, Schlüter A, Urreizti R, Tarnowski JM, Gavrilova RH, Ruiz M, Rodríguez-Palmero A, Fourcade S, Cogné B, Besnard T, Vincent M, Bézieau S, Folmes CD, Zimmermann MT, Klee EW, Pandey UB, Artuch-Iriberri R, Cousin MA, Pujol A and SHMT2 Working Group.

    Impairment of the mitochondrial one-carbon metabolism enzyme SHMT2 causes a novel brain and heart developmental syndrome

    ACTA NEUROPATHOLOGICA . 140(6): 971-975. Number of citations: 21

    [doi:10.1007/s00401-020-02223-w]

  • Del-Prado-Sánchez C, Armstrong-Moron J, Veiga C, Grixolli-Mazzon S, Garcia-Cazorla A, Julià-Palacios NA and Morales-Ballús M.

    Cataract in You-Hoover-Fong syndrome: TELO2 deficiency

    OPHTHALMIC GENETICS . 41(6): 656-658. Number of citations: 5

    [doi:10.1080/13816810.2020.1821382]

  • Mantegazza R, O'Brien FL, Yountz M, Howard JF Jr and REGAIN study group.

    Consistent improvement with eculizumab across muscle groups in myasthenia gravis

    Annals of Clinical and Translational Neurology . 7(8): 1327-1339. Number of citations: 19

    [doi:10.1002/acn3.51121]

  • Armangue-Salvador T, Olivé-Cirera G, Martínez-Hernandez E, Sepulveda M, Ruiz-Garcia R, Muñoz-Batista M, Ariño H, González V, Felipe-Rucián A, Jesús Martínez-González M, Cantarín-Extremera V, Concepción Miranda-Herrero M, Monge-Galindo L, Tomás-Vila M, Miravet E, Málaga I, Arrambide G, Auger C, Tintoré M, Montalban X, Vanderver A, Graus F, Saiz A, Dalmau J and Spanish Pediatric anti-MOG Study Group.

    Associations of paediatric demyelinating and encephalitic syndromes with myelin oligodendrocyte glycoprotein antibodies: a multicentre observational study.

    LANCET NEUROLOGY . 19(3): 234-246. Number of citations: 196

    [doi:10.1016/S1474-4422(19)30488-0]

  • Murai H, Uzawa A, Suzuki Y, Imai T, Shiraishi H, Suzuki H, Okumura M, O'Brien F, Wang JJ, Fujita KP, Utsugisawa K and REGAIN Study Group.

    Long-term efficacy and safety of eculizumab in Japanese patients with generalized myasthenia gravis: A subgroup analysis of the REGAIN open-label extension study.

    JOURNAL OF THE NEUROLOGICAL SCIENCES . 407: 116419-116419. Number of citations: 13

    [doi:10.1016/j.jns.2019.08.004]

  • Andersen H, Mantegazza R, Wang JJ, O'Brien F, Patra K, Howard JF Jr and REGAIN Study Group.

    Eculizumab improves fatigue in refractory generalized myasthenia gravis.

    QUALITY OF LIFE RESEARCH . 28(8): 2247-2254. Number of citations: 32

    [doi:10.1007/s11136-019-02148-2]

  • Muppidi S, Utsugisawa K, Benatar M, Murai H, Barohn RJ, Illa I, Jacob S, Vissing J, Burns TM, Kissel JT, Nowak RJ, Andersen H, Casasnovas C, de Bleecker JL, Vu TH, Mantegazza R, O'Brien FL, Wang JJ, Fujita KP, Howard JF Jr and Regain Study Group.

    Long-term safety and efficacy of eculizumab in generalized myasthenia gravis.

    MUSCLE & NERVE . 60(1): 14-24. Number of citations: 151

    [doi:10.1002/mus.26447]

  • Julià-Palacios NA, Boronat S, Delgado I, Felipe A and Macaya A.

    Pediatric Klüver-Bucy Syndrome: Report of Two Cases and Review of the Literature.

    Neuropediatrics . 49(2): 104-111. Number of citations: 5

    [doi:10.1055/s-0037-1609036]

  • Rodriguez H, Ormazabal-Herrero A, Casado-Rio M, Arias AY, Oliva-Mussara C, Barranco-Altirriba M, Ricard Casadevall Llandrich, Francisco García Cuyás, Nascimento-Osorio A, Ortez-Gonzalez CI, Natera-de Benito D, Armangue-Salvador T, O'Callaghan-Gordo M, Julià-Palacios NA, Darling A, Ortigoza-Escobar JD, Fons-Estupina C, Garcia-Cazorla A, Perera A and Artuch-Iriberri R.

    Cerebrospinal Fluid Homovanillic and 5-Hydroxyindoleacetic Acids in a Large Pediatric Population; Establishment of Reference Intervals and Impact of Disease and Medication.

    CLINICAL CHEMISTRY . : .

    [doi:10.1093/clinchem/hvae139]